At present, there is no effective specific treatment available for<unk> . Treatment centers around intense glycemic control through diet, oral hypoglycemics and frequently insulin and management of heart failure symptoms. There is a clear correlation between increased glycemia and risk of developing<unk> , therefore, keeping glucose concentrations as controlled as possible is paramount. Thiazolidinediones are not recommended in patients with NYHA Class III or IV heart failure secondary to fluid retention. As with most other heart diseases, ACE inhibitors can also be administered. An analysis of major clinical trials shows that<unk>  patients with heart failure benefit from such a therapy to a similar degree as non-diabetics. Similarly, beta blockers are also common in the treatment of heart failure concurrently with ACE inhibitors.
Diabetic cardiomyopathy
Amyloid cardiomyopathy
Alcoholic cardiomyopathy
Ischemic cardiomyopathy
Viral cardiomyopathy
Dilated cardiomyopathy
Noncompaction cardiomyopathy
Cardiac amyloidosis